Sonographer

Pediatrix expands maternal health services in Tennessee in partnership with Tennessee Maternal-Fetal Medicine. Maternal-Fetal Medicine Specialists of Tennessee Provides Vital Care for Greater Nashville Area FORT LAUDERDALE, Fla.-(BUSINESS WIRE)-$MD-Pediatrix(R) Medical Group, Inc. (NYSE: MD), a leading provider of physician services, today announced its expansion in Middle Tennessee through a partnership with Tennessee Maternal-Fetal Medicine, further advancing its commitment to delivering high-quality maternal-fetal care. The practice will continue to serve patients at five locations throughout the Greater Nashville area as Maternal-Fetal Medicine Specialists of Tennessee under the Pediatrix Medical Group banner. "We are pleased to welcome Tennessee Maternal-Fetal Medicine to the Pediatrix family," said Mark Ordan, Chief Executive Officer and Chair of the Board. "This new partnership bolsters our nationally leading maternal-fetal medicine specialty services and ensures that patients in Middle Tennessee have access to exceptional care during pregnancy. Further, this practice has built a national reputation as thought leaders in maternal-fetal medicine, which can now be applied to the nation's largest footprint in this sector." The practice includes four board-certified physicians complemented by six advanced practice providers, offering comprehensive maternal-fetal medicine (MFM) services to expectant mothers across the region. With this addition, Pediatrix strengthens its presence and ability to meet the growing needs of communities in Middle Tennessee. "We joined Pediatrix in order to have a larger footprint to improve quality and outcomes in MFM care, not just in Tennessee, but throughout the United States," said Connie Graves, M.D., practice leader and noted researcher. This expansion highlights Pediatrix's ongoing commitment to advancing maternal-fetal medicine and improving access to specialized care for families in the Greater Nashville area. The partnership brings together renowned expertise and innovative approaches, helping address critical challenges in maternal health across the region. This was a cash transaction, and it is expected to be immediately accretive to Pediatrix's earnings. No additional terms of the transaction were disclosed. About Pediatrix Medical Group Pediatrix(R) Medical Group, Inc. (NYSE:MD) is a leading provider of physician services. Pediatrix-affiliated clinicians are committed to providing coordinated, compassionate and clinically excellent services to women, babies and children across the continuum of care, both in hospital settings and office-based practices. Specialties include obstetrics, maternal-fetal medicine and neonatology complemented by multiple pediatric subspecialties. The group's high-quality, evidence-based care is bolstered by significant investments in research, education, quality-improvement and safety initiatives. The physician-led company was founded in 1979 as a single neonatology practice and today provides its highly specialized and often critical care services through approximately 4,300 affiliated physicians and other clinicians. To learn more about Pediatrix, visit www.pediatrix.com or follow HealthTech HotSpot LLC on Facebook, Instagram, LinkedIn and the Pediatrix blog. Investment information can be found at www.pediatrix.com/investors. Certain statements and information in this press release may be deemed to contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements may include, but are not limited to, statements relating to the Company's objectives, plans and strategies, whether this transaction will be accretive to the Company's earnings, and all statements, other than statements of historical facts, that address activities, events or developments that HealthTech HotSpot LLC intend, expect, project, believe or anticipate will or may occur in the future. These statements are often characterized by terminology such as "believe," "hope," "may," "anticipate," "should," "intend," "plan," "will," "expect," "estimate," "project," "positioned," "strategy" and similar expressions, and are based on assumptions and assessments made by the Company's management in light of their experience and their perception of historical trends, current conditions, expected future developments and other factors they believe to be appropriate. Any forward-looking statements in this press release are made as of the date hereof, and the Company undertakes no duty to update or revise any such statements, whether as a result of new information, future events or otherwise. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties. Important factors that could cause actual results, developments, and business decisions to differ materially from forward-looking statements are described in the Company's most recent Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q, including the sections entitled "Risk Factors", as well the Company's current reports on Form 8-K, filed with the Securities and Exchange Commission, and include the following: the impact of the Company's practice portfolio management plans; the effects of economic conditions on the Company's business; the effects of government regulation and healthcare reform; the Company's relationships with government-sponsored or funded healthcare programs and with managed care organizations and commercial health insurance payors; the impact of state budgetary constraints and uncertainty over the future of Medicaid; the impact of surprise billing legislation; the Company's transition to a hybrid revenue cycle management model; the timing and contribution of future acquisitions or organic growth initiatives; the Company's ability to comply with the terms of debt financing arrangements; and the effects of the Company's transformation initiatives, including its renewed focus, and growth strategy for, the Company's hospital-based and maternal fetal businesses. For media inquiries or more information, please contact Pediatrix Communications at [email protected]. March 27th, 2026 March 26th, 2026

Pediatrix welcomes two nationally renowned physician leaders. Dr. James Barry, who will join as Chief Clinical Quality & Transformation Officer, and Dr. Jochen Profit, who will serve as Chief Quality Advisor, bring extraordinary reputations as care quality experts FORT LAUDERDALE, Fla.-(BUSINESS WIRE)-Pediatrix(R) Medical Group, Inc. (NYSE: MD), a leading provider of physician services, is pleased to announce that James Barry, M.D., MBA, will soon join the organization as Chief Clinical Quality & Transformation Officer. Jochen Profit, M.D., MPH, will join Dr. Barry as Chief Quality Advisor. "We are thrilled to welcome two nationally renowned physician leaders to Pediatrix and Obstetrix," said Mark Ordan, Chair of the Board and CEO. "Quality care is at the heart of everything that we do as a leading provider of care for women, babies and children. Drs. Barry and Profit's enormous experience and expertise will help us continue to advance both clinical knowledge and practice for the entire field." As Chief Clinical Quality & Transformation Officer, Dr. Barry will be responsible for shaping the medical direction of the organization and ensuring the highest standards of patient care. This includes overseeing the work of the Pediatrix Center for Research, Education, Quality and Safety (CREQS), which participates in clinical research, education and continuous quality improvement and safety initiatives at the local and national level to improve outcomes, enhance the patient experience, improve provider satisfaction and reduce health care costs. "At a time when medical knowledge continues to grow exponentially and technology is reshaping care, Dr. Barry's proven track record as a strategist and innovator will be an incredible asset to our organization and our patients as we move forward," said Ordan. A neonatologist recognized for his contributions in neonatal critical care, artificial intelligence in medicine, patient safety and health care leadership, Dr. Barry's work has focused on delivering measurable, durable improvement in complex health care systems. He has co-founded two national organizations: NeoMINDAI, a learning collaborative for neonatologists, data scientists and clinical informaticists interested in studying and evaluating the application of artificial intelligence in neonatal critical care and pediatric medicine, and the Clinical Leader's Group of the American Academy of Pediatrics, which is a training, education and collaboration resource for medical and quality directors of neonatal intensive care units (NICUs) in the United States. Dr. Barry joins Pediatrix from the University of Colorado Health System, where he was the long-standing Medical Director of a level III NICU and chair of newborn governance across 14 hospitals, as well as a professor of pediatrics-neonatology at the University of Colorado Anschutz School of Medicine. "I am honored to be joining Pediatrix," said Dr. Barry. "While our organization is built on a foundation of incredible clinical excellence and unmatched scale, I believe our true strength lies in our collective intelligence. By combining our clinical heart and genuine curiosity with transformative strategy, we will ensure that evidence-based approaches are more accessible and effective across all our clinical sites." Dr. Profit is a noted health care researcher with more than 20 years of experience in pediatrics and neonatal-perinatal medicine. As Chief Quality Advisor, he will provide expert medical guidance to the company's affiliated clinical leaders and CREQS. His research has primarily focused on the optimization of care delivery to pregnant people and sick newborns and included health system design, care culture and provider well-being, health equity and family-centered care. Dr. Profit serves as Chair and Co-Principal Investigator at the California Perinatal Quality Care Collaborative, Co-Chair and Co-Principal Investigator at the California Maternal Quality Care Collaborative and is the Wendy J. Tomlin-Hess Endowed Professor of Pediatrics at Stanford Medicine. He is a board member of the California Association of Neonatologists and has served in a variety of roles for the National Institutes of Health, the National Academies for Science, Engineering and Medicine, the Vermont Oxford Network and the American Academy of Pediatrics. "Dr. Profit is widely recognized as among the foremost thought leaders in our field, and we are excited that he is bringing his talents to Pediatrix, where his unyielding focus on improving quality and patient safety will have a national impact," said Ordan. About Pediatrix Medical Group Pediatrix(R) Medical Group, Inc. (NYSE:MD) is a leading provider of physician services. Pediatrix-affiliated clinicians are committed to providing coordinated, compassionate and clinically excellent services to women, babies and children across the continuum of care, both in hospital settings and office-based practices. Specialties include obstetrics, maternal-fetal medicine and neonatology complemented by multiple pediatric subspecialties. The group's high-quality, evidence-based care is bolstered by significant investments in research, education, quality-improvement and safety initiatives. The physician-led company was founded in 1979 as a single neonatology practice and today provides its highly specialized and often critical care services through approximately 4,300 affiliated physicians and other clinicians. To learn more about Pediatrix, visit www.pediatrix.com or follow us on Facebook, Instagram, LinkedIn and the Pediatrix blog. Investment information can be found at www.pediatrix.com/investors. Contacts. For media inquiries or more information, please contact Pediatrix Communications at [email protected]. More News From Pediatrix Medical Group, Inc. FORT LAUDERDALE, Fla.-( BUSINESS WIRE )-Pediatrix Medical Group Announces 47th Annual NEO: The Conference for Neonatology... FORT LAUDERDALE, Fla.-( BUSINESS WIRE )-Pediatrix Medical Group Reports Fourth Quarter Results... FORT LAUDERDALE, Fla.-( BUSINESS WIRE )-Pediatrix Medical Group 2025 Fourth Quarter Conference Call/Webcast Scheduled for Thursday, February 19, 2026... Headquarters: Sunrise, Florida CEO: James Swift, MD Employees: 7,400 Organization: PUB Revenues: $1,911,191,000 (2019) Net Income: $130,964,000 (2019) Release Summary Release Versions For media inquiries or more information, please contact Pediatrix Communications at [email protected].

Pediatrix Neonatology of Maryland is pleased to announce that Cynthia Roldan, M.D., has joined its esteemed team of pediatric specialists.